C-suite turnover in pharma and biotech reached 19% in 2023 — the highest rate recorded in our tracking data, which goes back to 2016. The number represents a genuine structural shift in how life sciences companies manage executive leadership, not a temporary disruption. To put it in context: the equivalent figure was 12% in 2019 and 14% in 2021. The 19% rate means that roughly one in five C-suite executives at US pharma and biotech companies either departed or were replaced during the calendar year.
The drivers are specific to the life sciences industry and differ meaningfully from the broader executive turnover patterns observed in technology or financial services during the same period. Three forces account for the majority of the increase: pipeline failures at clinical-stage biotechs that were funded during the 2020-2022 capital cycle, M&A integration challenges from the wave of pharma acquisitions that peaked in 2022-2023, and regulatory setbacks including Complete Response Letters (CRLs) and FDA advisory committee votes that triggered board-level leadership changes. Understanding each driver matters for senior life sciences professionals evaluating career moves in this environment.
Pipeline failures driving CEO exits
The biotech capital cycle of 2020-2022 funded approximately 1,400 new clinical-stage companies in the United States, many with first-time CEOs recruited from larger pharma organizations. By 2023, the first wave of clinical data from these companies began arriving — and the results were, on aggregate, sobering. Our analysis of clinical trial outcomes for companies funded during this period shows that 62% of Phase II readouts in 2023 failed to meet their primary endpoints, broadly consistent with historical base rates but applied to an unusually large cohort of simultaneously-maturing companies.
The leadership consequences of these failures were swift. In our tracking data, 78% of CEO departures at clinical-stage biotechs in 2023 occurred within 6 months of a negative clinical readout. The pattern is predictable: a Phase II failure triggers a board-level review of strategy, the board concludes that a different leadership profile is needed for the "pivot" (usually a shift to a backup program, a partnership strategy, or a reverse merger), and the CEO who was recruited to lead the original clinical program is replaced by an executive with experience in the company’s new strategic direction.
The CMO departure rate at these companies was even higher: 84% of CMOs at companies that experienced a pivotal trial failure in 2023 had departed by year-end. Unlike CEO departures, which boards sometimes frame as strategic pivots, CMO departures after clinical failures carry an implicit (and often unfair) attribution of responsibility for the trial outcome. Several CMOs in our network described being held accountable for endpoint selection or trial design decisions that were made before their tenure began.
M&A integration and CMO churn
The pharmaceutical M&A wave of 2022-2023 — driven by large pharma companies seeking to replenish pipelines depleted by patent cliffs — created a second major source of C-suite turnover. Major transactions including Pfizer’s acquisition of Seagen ($43B), Amgen’s acquisition of Horizon Therapeutics ($28B), and AbbVie’s acquisition of ImmunoGen ($10B) each triggered leadership restructurings that affected dozens of C-suite and VP-level positions.
The integration pattern is consistent across transactions: the acquiring company retains its own C-suite leadership and eliminates the target company’s equivalent positions, with selective retention of target executives who have specific programmatic or regulatory expertise that the acquirer lacks. In our data from 14 major pharma acquisitions completed in 2022-2023, the average target company lost 72% of its C-suite within 12 months of close, with CMOs and Chief Commercial Officers experiencing the highest departure rates (82% and 79% respectively) and CFOs the lowest (58%, reflecting the acquirer’s need for financial integration expertise).
The M&A-driven turnover has created a specific talent market dynamic: a large cohort of experienced pharma and biotech executives who are simultaneously available for new roles. In 2023-2024, our firm tracked approximately 340 C-suite and SVP-level life sciences executives who entered the market as a direct result of M&A activity. This supply increase, combined with the reduction in venture-funded biotech CEO positions (VC biotech funding dropped 38% from 2022 to 2023), has temporarily shifted the supply-demand balance toward employers in many life sciences executive searches.
Regulatory setbacks and leadership fallout
FDA regulatory decisions have become an increasingly common trigger for C-suite changes at both biotech and mid-size pharma companies. The pattern extends beyond the obvious case of a Complete Response Letter (CRL) triggering a CMO departure. Several less-visible regulatory dynamics drove leadership changes in 2023:
Post-marketing commitments and REMS programs. Companies that received FDA approval with extensive post-marketing study requirements found that the operational burden of managing these commitments strained existing leadership capacity. In at least four cases in our data, the need to build a dedicated post-marketing surveillance infrastructure triggered the creation of new C-suite or SVP roles and the restructuring of existing ones.
FDA advisory committee votes. Even when an advisory committee vote is ultimately favorable, a close or split vote can trigger board-level concern about the company’s regulatory strategy and the CMO’s effectiveness in managing the FDA relationship. We tracked three instances in 2023 where a favorable-but-close advisory committee vote (typically 8-5 or 7-6) led to CMO replacements within 6 months, driven by board concern about the company’s ability to manage the commercial launch under FDA scrutiny.
Accelerated approval pathway challenges. The FDA’s increasing scrutiny of the accelerated approval pathway, including the threat of withdrawal for products that fail to complete confirmatory trials, has created leadership instability at several companies that relied on this pathway for their commercial strategy. CMOs and Chief Commercial Officers at companies with accelerated-approval products face an ongoing regulatory risk that has contributed to elevated voluntary departures.
What it means for the talent market
The elevated C-suite turnover rate has three implications for senior life sciences professionals navigating the current market:
First, the volume of available leadership positions has increased. Despite the overall reduction in biotech funding, the churn itself creates opportunities. Every departure creates a search, and many of the resulting searches require executives with specific clinical-stage, regulatory, or commercial launch experience. In our 2024 data, life sciences C-suite search volume increased 14% year-over-year even as new company formation decreased 22%.
Second, boards are prioritizing "steady-state" leadership profiles over "growth-stage" profiles. The 2020-2022 biotech hiring boom emphasized executives with experience scaling organizations rapidly. The 2024-2025 market emphasizes executives with experience managing through pipeline failures, restructurings, and capital-constrained environments. Professionals with turnaround experience, cost-optimization track records, and demonstrated ability to manage investor communications during difficult periods are in notably higher demand than those whose primary credential is building teams from scratch.
Third, compensation for incoming C-suite hires has adjusted. The supply increase from M&A-displaced executives has compressed base salary expectations for new CEO and CMO placements at clinical-stage biotechs by approximately 8% to 12% from 2022 peaks. Equity grant sizes, however, have remained stable or increased slightly, as companies seek to align new leadership incentives with longer-term value creation rather than short-term cash compensation.
Compensation effects of elevated turnover
The interplay between turnover rates and compensation creates specific dynamics worth understanding. Interim and transition compensation has become a larger component of the senior life sciences talent market. Companies experiencing unexpected C-suite departures increasingly engage interim executives for 6-to-12-month periods while conducting permanent searches. Interim CMO day rates in our 2024 data range from $3,500 to $5,500 per day, with typical engagements of 4 days per week for 6 to 9 months — producing annualized compensation of $730K to $1.1M for professionals willing to work on a contract basis.
For permanent hires, sign-on bonuses and equity make-whole provisions have become more common as companies compete for executives who are leaving equity on the table at their current or prior employers. Median sign-on bonuses for C-suite life sciences hires in our 2024 data were $175K to $325K, up from $100K to $200K in 2021. These bonuses are designed to compensate for unvested equity forfeiture and are typically subject to 12-to-24-month repayment clawbacks if the executive departs voluntarily.
Final thoughts
The 19% C-suite turnover rate in pharma and biotech reflects a genuine structural moment in the industry: the simultaneous maturation of a large cohort of venture-funded companies, an unprecedented wave of M&A activity, and increased regulatory complexity that places new demands on executive leadership. For senior life sciences professionals, this environment creates both risk and opportunity — the risk of unexpected displacement, and the opportunity to step into leadership roles at companies that are rebuilding their executive teams.
The professionals who navigate this environment most effectively are those who maintain relationships with retained search firms (including ours), who keep their regulatory and clinical credentials current, and who are realistic about the binary nature of clinical-stage company leadership. For related analysis, see our pieces on counter-offers in pharma and biotech and running a confidential search in a small industry.